CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 52 enrolled
Drug / intervention
Zinc gluconatedietary
Likely dose
Zinc gluconate daily (specific dose not stated)AI-extracted
Key inclusion· 6
  • ✓HIV-1 infection confirmed
  • ✓Age 18 years or older
  • ✓Zinc level ≤0.75 mg/L (low baseline zinc)
  • ✓Stable antiretroviral regimen with no planned changes during study
Key exclusion· 8
  • ✕Pregnancy or lactation
  • ✕Presence of inflammatory condition
  • ✕Active neoplastic disease requiring chemotherapy or immunosuppressive drugs
  • ✕Known cardiovascular disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02856269
NCT02856269N/ACompleted
CompareCT.gov

Zinc Supplementation and Cardiovascular Risk in HIV

Grace McComsey·interventional·Posted Aug 4, 2016·Updated Feb 11, 2022

In Brief

A clinical study evaluating Zinc gluconate for HIV and Inflammation. Completed, enrolled 52 participants across 1 site.

Detailed Summary

The purpose of this pilot study is to determine whether zinc supplementation significantly affects immune activation in HIV-infected subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Inflammation
CountriesUnited States
CollaboratorsNational Center for Complementary and Integrative Health (NCCIH)

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedAug 4, 2016
Enrollment StartSep 1, 2016
Primary CompletionApr 16, 2018
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.9 years ago

Interventions

Zinc gluconatedietary

Participants will take a daily dose of zinc gluconate.